Intercept Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Intercept Pharmaceuticals has a total shareholder equity of $71.8M and total debt of $223.9M, which brings its debt-to-equity ratio to 311.6%. Its total assets and total liabilities are $393.2M and $321.3M respectively.
Key information
311.6%
Debt to equity ratio
US$223.86m
Debt
| Interest coverage ratio | n/a |
| Cash | US$322.71m |
| Equity | US$71.85m |
| Total liabilities | US$321.32m |
| Total assets | US$393.16m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: I4P's short term assets ($383.4M) exceed its short term liabilities ($90.8M).
Long Term Liabilities: I4P's short term assets ($383.4M) exceed its long term liabilities ($230.5M).
Debt to Equity History and Analysis
Debt Level: I4P has more cash than its total debt.
Reducing Debt: I4P's debt to equity ratio has reduced from 383.3% to 311.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: I4P has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if I4P has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.